Navigation Links
IDEXX Laboratories Announces Fourth Quarter and Full Year Results
Date:1/30/2009

costs is not representative of ongoing operations and is not indicative of future performance. Specific acquisition-related discrete costs do not include amortization expense related to acquired intangible assets. We applied the statutory income tax rates of the applicable tax jurisdictions to calculate the after-tax impact of these discrete items. (2) We believe that the impact of the disposition of certain pharmaceutical product lines and the related restructuring of the remaining pharmaceutical business in the fourth quarter is not indicative of future performance because significant transactions and related costs of a similar nature are not likely to recur within a reasonable period. In the fourth quarter of 2008 we completed a transaction to sell our ACAREXX and SURPASS pharmaceutical products and a product currently under development, which were a part of our CAG segment, and subsequently restructured the remaining pharmaceutical business. (3) The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation.

    IDEXX Laboratories, Inc. and Subsidiaries
    Non-GAAP Financial Measures
    Amounts in thousands except per share data (Unaudited)

                                               Twelve Months Ended
                                                             Income from
                                        Gross Profit         Operations
                                     Dec. 31,   Dec. 31,  Dec. 31,   Dec. 31,
                                       2008     2007       2008      2007

    GAAP measurement                $529,766  $463,522  $172,456  $136,183
       % of revenue                    51.7%     50.2%     16.8%     14.8%
    Write-downs of certain
     pharmaceutical assets (1)             -    10,138         -    10,138
    Ac
'/>"/>
SOURCE IDEXX Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine news :

1. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
2. IDEXX Laboratories Names William Brown Corporate Vice President
3. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
4. IDEXX Laboratories to Release 2008 First Quarter Financial Results
5. IDEXX Laboratories Announces Increase in Share Repurchase Program
6. IDEXX Laboratories Announces Fourth Quarter Results
7. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
8. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
10. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
11. Metametrix Announces Acquisition of Accu-Chem Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... As the Ebola outbreak in Liberia worsens, ... both purchase critical emergency supplies locally, as well as ship ... supplies will contain materials used to control the spread of ... of the country. , With a large programmatic presence ... the Ebola outbreak in the region. The current epidemic remains ...
(Date:7/29/2014)... 29, 2014 Many people complain about their ... do each morning is put on glasses to see their ... same individuals also may be dissatisfied with their vision even ... Cataracts may cause difficulty driving, especially at night due to ... find one’s golf ball, see the TV, sew or cross ...
(Date:7/29/2014)... Thompson HealthDay Reporter , TUESDAY, ... and good sleep can protect the body against the negative ... a cellular level, researchers report. A study involving hundreds ... increased shortening of telomeres, the protective caps at the ends ... found that over a one-year period, the more stressors a ...
(Date:7/29/2014)... of living donor kidney transplants receive steady follow-up ... be monitored. To make follow-up care more accessible, ... WAG) are collaborating to launch the first program ... at no charge to living kidney donors. , ... redeemable at more than 4,500 Walgreens pharmacies and ...
(Date:7/29/2014)... Most people want to turn back the clock ... about their appearance. There are anti aging microcurrent ... that can help them to look their absolute best. ... oriented anti-aging procedures that are noninvasive and they adding some ... with cellulite. To accommodate, they are also in the ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3Health News:Caring for donors 2Health News:Caring for donors 3Health News:Supreme Skin Announces Plans for a Grand Re-opening for Their Noninvasive Anti Aging Microcurrent Face and Body Treatments In Asheville, NC 2
... 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... the development, manufacture and commercialization of,a broad range of ... announced financial results for the fourth quarter and fiscal ... Financial Results , Revenue in ...
... of baby boomers with eye-ailments and soaring medical ... diet supplements to protect their eyes and curb ... supplements to alleviate blinding diseases such as age-related ... growth avenues in the market.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ...
... (Dublin, Ohio), the psychiatric practice of Adam Brandemihl, M.D., Board Certified ... Adult ADD. He discusses ten ways of coping with adult ADD ... ... 9, 2009 -- With the continued recession and struggling economy, keeping ...
... as the community,s new medical director. White, a Board-certified internal and ... substantial, relevant experience to Park Springs, a continuing care retirement community ... ... March 6, 2009 -- Park Springs is pleased to announce Dr. ...
... treatment provider and renowned male hormone replacement experts ... publicity concerning professional athletes within MLB testing positive ... growth hormone) may have on men suffering from ... negative image being portrayed by professional athletes -- ...
... analysis has found that certain variations in genes that ... Hodgkin disease. Published in the April 1, 2009 issue ... American Cancer Society, the study indicates that differences in ... individuals, susceptibility to this type of cancer. , Proteins ...
Cached Medicine News:Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:Frost & Sullivan: Ageing Population and Availability of Preventative Medicines Propels Growth of European Eye Health Ingredients Market 2Health News:Frost & Sullivan: Ageing Population and Availability of Preventative Medicines Propels Growth of European Eye Health Ingredients Market 3Health News:Frost & Sullivan: Ageing Population and Availability of Preventative Medicines Propels Growth of European Eye Health Ingredients Market 4Health News:Frost & Sullivan: Ageing Population and Availability of Preventative Medicines Propels Growth of European Eye Health Ingredients Market 5Health News:How to Win the Battle with Adult ADD in the Workplace 2Health News:How to Win the Battle with Adult ADD in the Workplace 3Health News:Park Springs Names New Medical Director 2Health News:Park Springs Names New Medical Director 3Health News:Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity 2Health News:Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity 3Health News:Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity 4Health News:DNA differences may influence risk of Hodgkin disease 2
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- The global microbial identification market ... applications, end users, and geographies. Genotypic technology is ... identification market. This favorable growth is attributed to ... the time required for microbial identification along with ... genotypic methods have high applications in clinical diagnostics ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
(Date:7/29/2014)... Holding Company (Nasdaq: ESRX ) announced 2014 ... of $515.2 million, or $0.67 per diluted share.  Adjusted ... was $1.23 for the second quarter. 1 ... with scale, alignment and innovative solutions to lower costs, manage ... stated George Paz, chairman and chief executive officer.  "We ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... GTHR.PK), announces it will soon begin offering its Real Time,PCR ... , GeneThera is set ... January of 2009. According to GeneThera Chairman, Dr. Tony ... PCR test for Johne,s disease,called HerdGuard(TM) by the first of ...
... A new cancer treatment is,realizing outstanding results against ... large, stage 4 tumor was reduced in size ... no longer could be definitely,identified on scans. Pancreatic ... diagnosis. NeoPlas Innovation,s combination of FDA-approved drugs,appears to ...
Cached Medicine Technology:GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4New Cancer Treatment Shrinks Pancreatic Tumor 2
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and Quality ... are designed to assist POLs, clinics and ... designed to assure accuracy of patient lab ... requirements. Participation provides the opportunity to earn ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: